A comprehensive panel of tests known as a liver function test (LFT) will check for ALT and AST and may also check for other enzymes. Your healthcare provider may order an LFT for a number of ...

Predictive Safety Testing Consortium have proposed glutamate dehydrogenase (GLDH) as a more liver-specific biomarker for ...

A Phase 2 clinical trial finds that ALT flares are common in hepatitis D patients treated with pegylated interferon-alpha, ...

Researchers from Critical Path Institute’s Predictive Safety Testing Consortium have proposed glutamate dehydrogenase (GLDH) as a more liver-specific biomarker for detecting liver injury, supporting ...

physicians often express concerns about the safety of initiating statin therapy for treating hyperlipidemia. While rare, ...

Fatty liver disease, also known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), is a silent but serious ...

The U.S. Food and Drug Administration's (FDA) Biomarker Qualification Program (BQP) is currently reviewing C-Path's Full Qualification Package (FQP) to qualify GLDH as a liver safety biomarker. The ...

Surrozen is discontinuing its sole clinical-stage candidate and pivoting to its preclinical ophthalmology pipeline after the ...